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Hereditary sensory neuropathy type I (HSN1) is a common degenerative disorder of peripheral sensory neurons. HSN1 is caused by
mutations in the gene, encoding the long chain base 1 of serine palmitoyltransferase (SPT) [Nat. Genet. 27 (2001) 309]. Here, we show a
44% reduction of SPT activity in transformed lymphocytes from HSN1 patients with mutation T399G in the SPTLC1 gene. However, the
decrease in SPT activity had no effect on de novo sphingolipid biosynthesis, cellular sphingolipid content, cell proliferation and death
(apoptosis and necrosis). The removal of extracellular sphingolipids did not affect viability of HSN1 cells. We also found no significant
difference in whole blood counts, viability, and permeability to Triton X-100 of primary lymphocytes from HSN1 patients. These results
suggest that, despite the inhibition of mutant allele, the activity of nonmutant allele of STP may be sufficient for adequate sphingolipid
biosynthesis and cell viability. Therefore, the neurodegeneration in HSN1 is likely to be caused by subtler and rather long-term effect(s) of
these mutations such as loss of a cell-type selective facet of sphingolipid metabolism and/or function, or perhaps accumulation of toxic
species, including abnormal protein(s) as in other neurodegenerations.
D 2004 Elsevier B.V. All rights reserved.Keywords: Hereditary sensory neuropathy; Serine palmitoyltransferase; Transformed lymphocyte; Sphingolipid; Cell proliferation; Cell death1. Introduction
Hereditary sensory neuropathy type I (HSN1) is an
autosomal-dominant disorder of peripheral sensory neu-
rons with progressive degeneration of neurons in dorsal
root ganglia and an onset during the second or third
decades of life. Initial symptoms include dismal sensory
loss, commencing in the feet, followed by distal muscle
wasting and weakness, chronic skin ulcerations, leading to
distal amputations [2,3].
Our group has mapped the gene responsible for HSN1 to
chromosome 9q22.1–q22.3 [4–7]. Recently, we found three
HSN1 mutations in subunit 1 of SPT (SPTLC1) that cause
HSN1 [1]. Our findings were independently confirmed [8].
The most common mutation within HSN1 families of Aus-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: vdedov@med.usyd.edu.au (V.N. Dedov).tralian/English origin (seven families) is a single base sub-
stitution T399G in exon 5 of SPTLC1 coding region. The
mutation results in a single amino acid substitution of
cysteine by tryptophan (C133W) (Fig. 1). Other less common
mutations in SPTLC1 gene are G398A and T431A. There are
no mutations in the subunit 2 of the enzyme [9].
SPT (EC 2.3.1.50) is a pyridoxal-5V-phosphate dependent
enzyme, which is the first and rate-limiting enzyme in
sphingolipid biosynthesis. It catalyses condensation of serine
and palmitoyl-CoA to produce 3-ketodehydrosphinganine
(3-KDS). 3KDS is converted into sphingomyelins and gly-
cosphingolipids via the chain of intermediate products (Fig.
2). As some of these products (i.e., sphinganine-1-phosphate
and ceramide) are biologically active, numerous studies
highlighted the importance of de novo synthesis of sphingo-
lipids in signal transduction and activation of cell death
pathways (reviewed in Refs. [10–12]). SPT consists of two
hetero subunits SPTLC1 and SPTLC2 in humans (or LCB1
and LCB2 in mammalians) (reviewed in Ref. [13]). The
enzyme is ubiquitous. SPT activity was found in all tissues
of rat [14] and SPT immunoreactivity was found in all human
tissues [15]. On intracellular level, SPT is thought to be
Fig. 1. HSN1-related mutation T399G in exon 5 of SPTLC1. (A)
Electropherogram showing the c.399T!G sequence variation in part of
exon 5, resulting in the Cys133Trp missense mutation in HSN1families (1,
2, 6, 16, 22–24) of Australian/English origin [1]. (B) The corresponding
genomic sequence of a control person.
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a nuclear association has also been proposed [15].
The effects of HSN1 mutations on SPT activity and cell
viability were recently investigated in vitro. In Saccharomy-
ces cerevisiae, the expression of HSN1 mutations inhibited
SPT activity, causing cell death [18]. Similarly, overproduc-
tion of mutant LCB1, carrying C133Yor C133W mutations,
inhibited total SPT activity in CHO cells. The inhibition
occurred despite the presence of wild-type LCB1. Mutant
LCB1 was capable of forming complexes with LCB2, but
these complexes were inactive as SPT. In human HSN1
lymphoblasts (transformed lymphocytes), the C133Y and
C133W mutations did not alter the steady state levels of
SPTLC1 and SPTLC2 subunits. However, these cells had
reduced SPT activity by 75% and sphingolipid biosynthesis
by 45%. It was concluded that HSN1 mutations confer
dominant-negative effects on SPT enzyme activity [19].
However, it is unclear how the extensive expression of
mutant SPTLC1 in the usual physiologic context of a normal
wild-type allele, as found in cells of HSN1 patients, affects
SPTactivity, cellular sphingolipid amounts, cell proliferation,
and viability. As this is a critical starting point for under-
standing the pathogenesis of HSN1, in the present study, we
investigated correlation between SPTactivity and viability of
lymphocytes with HSN1 mutation T399G in SPTLC1 gene.
We showed that, despite the reduction of SPT activity, the
rates of sphingolipid biosynthesis, cell proliferation, and
death in HSN1 cells were not changed.Fig. 2. Biosynthetic pathway of sphingolipids in mammalian cells.2. Methods and techniques
2.1. Subjects and whole blood counts
Hereditary sensory neuropathy was diagnosed clinical-
ly as a Charcot–Marie–Tooth type II (CMT2) phenotypewith dense sensory loss and a history of painless injuries
and chronic skin ulceration of the hands and feet in at
least one affected family member. Neurophysiological
studies showed loss of sensory action potentials and
axonal degeneration. Nine patients of Australian/English
origin, four males and five females, were chosen for this
study. These nine HSN1 family members were found in
our previous studies [1] as having a mutation T399G.
Informed consent and ethical approval were obtained,
according to the Concord Hospital Human Ethics Com-
mittee guidelines. Whole blood counts were performed
according standard protocols of the Haematology Labo-
ratory of the Concord Hospital.
2.2. Epstein–Barr virus (EBV) transformation of lympho-
cytes and cell culture
Lymphocytes were isolated using Ficoll gradient cen-
trifugation and transformed with EBV as described else-
where [20]. The EBV lymphocytes were cultured in
RPMI 1640 medium supplemented with 10% fetal calf
serum (FCS), 40 AM L-glutamine, 20 mM HEPES buffer
(pH 7.4), 50 units/ml penicillin G, 50 Ag/ml streptomycin
sulfate, and 1.25 Ag/ml amphotericin B in a 5% CO2
atmosphere at 37 jC.
2.3. DNA sequences
Transformed lymphocytes from HSN1 patients and
controls were collected. DNA was isolated, purified,
and amplified by PCR with SPTex5-F and SPTex5-R
primers as described elsewhere [1]. DNA sequencing was
performed by a DYEnamic ET Terminator Cycle Se-
quencing Kit (Amersham Pharmacia Biotech). Then, the
sequencing reactions were loaded on the ABI Prism3700
DNA Analyzer (Perkin Elmer Applied Biosystems). The
data were collected and analyzed via the ABI Data
Collection version 1.1. and DNA Sequencing Analysis
version 3.6 software, respectively.
Fig. 3. SPT activity and sphingolipid synthesis. (A) SPT activities in
transformed lymphocytes from control individuals (Control) and HSN1
patients (HSN1). (B) Average SPT activities in controls and HSN1 cells.
*P>0.005. (C) Rates of total sphingolipid synthesis in transformed
lymphocytes from control individuals and HSN1 patients. (D) Average
rates of total sphingolipid synthesis in controls and HSN1 cells. (E)
Correlation between SPT activity and rates of total sphingolipid synthesis in
17 cultures of transformed lymphocytes. R-correlation coefficient between
two data sets. R varies from 0 (no correlation) and 1 (100% correlation).
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Microsomes from transformed lymphocytes were pre-
pared using procedure described elsewhere [19]. Incor-
poration of [3H]serine into 3KDS was assayed based on
a previously described method [21,22]. Briefly, freshly
prepared microsomal pellets were dissolved in 0.1 ml of
reaction buffer [0.1 M HEPES pH 8.3, 5 mM DTT, 2.5
mM EDTA, and 0.05 mM pyridoxal phosphate (PLP),
0.2 mM palmitoyl-CoA (P-CoA), and 1 mM L-[3H]serine
(20 mCi/mmol)]. The final protein concentration was
0.1–0.3 mg protein per reaction. A control tube with
no P-CoA added was included for each sample. The
reaction has been measured over 10 min three times for
each experiment. The amounts of 3KDS formed were
quantified using scintillation counting counted using a
Wallac 1410 liquid scintillation counter (Perkin Elmer
Life Sciences, Boston, MA). Protein concentrations were
determined by RC DC Protein assay (Bio-Rad Labora-
tories, CA 94547) using bovine serum albumin (BSA) as
standard.
2.5. Sphingolipid biosynthesis
The rates of sphingolipid biosynthesis were deter-
mined by metabolic labeling of cellular sphingolipids
with [3H]serine in intact transformed lymphocytes as
described [21]. Briefly, 3–4 106 cells were incubated
in 2–4 ml of fresh medium in the presence of 10 ACi L-
[3H]serine at 37 jC for 2 and 24 h. Cell were collected
by centrifugation and washed twice in phosphate-buffered
saline (4 jC) before isolation of total lipids. Individual
lipids were separated by thin-layer chromatography
(TLC) using HPTLC silica gel 60 plates (10 10 cm).
Separated by TLC sphingolipids were visualized in
iodine vapor together with co-chromatographed standards
[23]. Specific spots were scraped and counted using a
Wallac 1410 liquid scintillation counter (Perkin Elmer
Life Sciences). The values of lipid labeling were nor-
malized for protein.
2.6. Sphingolipid content
The cell pellets were extracted and analyzed for
sphingolipids using essentially the conditions described
[24,25], which utilizes a combination of normal-phase-
and reversed-phase high-performance liquid chromatogra-
phy to separate the sphingolipid classes followed by
electrospray tandem mass spectrometry (ESI-MS/MS) on
a PE-Sciex API 3000 triple quadrupole mass spectrometer
equipped with a turboionspray source. Dry N2 was used
as the nebulizing gas at a flow rate of 6 l/min. The
ionspray needle was held at 5500 V, while the orifice and
ring voltages were kept low (40 and 220 V, respectively)
to prevent collisional decomposition of molecular ions
before entry into the first quadrupole and the orifice
V.N. Dedov et al. / Biochimica et170temperature was set to 500 jC. N2 was used to colli-
sionally induce dissociations in Q2, which was offset
from Q1 by 40–50 V. Q3 was then set to pass molec-
ularly distinctive product ions (N ions) of m/z 264.2 for
sphingosines and two mass units higher for sphinganines).
Sphingomyelins were followed by loss of the phospho-
choline headgroup. Multiple reaction monitoring (MRM)
scans were acquired by setting Q1 and Q3 to pass the
precursor and product ions of the most abundant sphin-
golipid molecular species. Quantitation was achieved by
spiking the samples before extraction with the internal
standards (from Avanti Polar Lipids) as described [25].
Bioph2.7. DNA synthesis assay
Cell proliferation was measured by [3H]thymidine
incorporation assay as previously described [20]. Briefly,
3–5 105 cells/ml EBV-lymphocytes were incubated for
6 h with 1 ACi/ml [3H]thymidine, 25 Ci/mmol (Amer-
sham Biosciences, Castle Hill, NSW, Australia). After
incubation, cells were collected on glass filters (Pall Life
Sciences, Lane Cove, NSW, Australia) and washed with
cold PBS. Radioactivity was measured using a Wallac
1410 liquid scintillation counter (Perkin Elmer Life
Sciences).
2.8. Assessment of viable, apoptotic, and necrotic cells
Apoptotic and necrotic cells were detected with
Vibrantk Apoptosis Assay Kit 2 (Molecular Probes,
Eugene, OR) according to the manufacturer’s manual.
Briefly, 3–10 105 cells were collected from cultures,
triturated with Pasteur pipette to break up clusters, and
washed with cold PBS. Then, cells were stained with 5
Al Annexin-V per 100 Al of cell suspension and 15
AM propidium iodide (PI) for 15 min. Immediately
after staining, samples were analyzed by flow cytom-
etry (FL1 channel for Alexa-488 and FL3 channel for
PI). Phosphatidylserine expression on the plasma mem-
brane of apoptotic cells was detected with Annexin-V
conjugated with Alexa-488, whereas PI stained necrotic
cells [26].
V.N. Dedov et al. / Biochimica etFig. 4. Sphingolipid content. The steady state levels of six most common sphingol
(D), sphinganine (E), and sphingosine-1-P (F)] were measured in transformed lym
as described in Methods and techniques.2.9. Flow cytometry and calculations
Samples were analyzed using a FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA) equipped with
a standard argon laser for 488-nm excitation and with 530/
30 nm band pass (FL1), 585/42 band pass (FL2), and 670
long pass (FL3) fluorescence filters. All data were pro-
cessed and analyzed using the CellQuest software (Becton
Dickinson). A gating function was used to distinguish cell
populations. The mean characteristics of cells populations
were calculated from at least three independent experiments
and statistically processed using Student’s t test. All other
experiments were also repeated at least three times and
presented as average values + S.D.
2.10. Chemicals
If not specified otherwise, all chemicals were analytical
grade from Sigma (St. Louis, MO). ISP-1 (myriocin) was
from Biomol (Plymouth Meeting, PA).
ysica Acta 1688 (2004) 168–175 1713. Results
3.1. SPT activity in HSN1 cells
For the present study, we collected blood samples from
nine HSN1 patients of Australian/English origin (four
males and five females). All of them carried the mutationipids [sphinganine (A), ceramide (B), glucosylceramide (C), sphingomyelin
phocytes from HSN1 patients (HSN1) and unaffected individuals (Control)
Fig. 5. Proliferation and cell death of transformed lymphocytes. Trans-
formed lymphocytes were seeded at 0.25 106 cells/ml and observed for
8 days in the presence of 10% FCS (diamonds and squares) or 1%
Nutridoma (triangles and circles). Diamonds and triangles depict control
cells. Squares and circles depict HSN1 cells. Cell death was assessed using
an apoptosis kit (see Methods and techniques for details). Changes in
numbers of (A) viable, (B) apoptotic, and (C)–necrotic cells were
monitored.
Table 1
Whole blood counts of unaffected (control) donor and HSN1 patient
samples
Test Reference range Units Control HSN1
Average S.D. Average S.D.
Hemoglobin 115–165 g/l 136.8 12.7 141.4 11.1
WBCa 4.0–11.0 109/l 6.96 0.84 6.46 0.91
Platelets 150–450 109/l 290.4 27.5 259.6 45.2
Red cells 4.5–6.5 1012/l 4.35 0.55 4.67 0.40
Hematocrit 0.37–0.47 0.39 0.04 0.41 0.04
MCV 79–97 fl 89.1 3.98 88.2 2.14
MCH 27–33 pg 30.6 1.46 30.3 1.03
MCHC 320–360 g/l 342.8 4.1 343 4.7
Neutrophils 2.0–7.5 109/l 4.3 0.57 3.64 0.65
Lymphocytes 1.5–4.0 109/l 2.02 0.57 1.86 0.34
Monocytes 0.2–0.8 109/l 0.54 0.18 0.74 0.31
Eosinophils 0.04–0.4 109/l 0.16 0.09 0.14 0.05
Basophils 0.0–0.10 109/l 0.04 0.05 0.08 0.04
The data present averageF S.D. from five patients and five age- and
gender-matched controls.
a White blood cells.
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than female patients (56.8F 12.3 vs. 38.0F 9.8 years old).
This is consistent with the known earlier onset of the
disease in females [2,3]. As a control, we collected blood
samples from unaffected individuals (four males and four
females) of corresponding gender and age (four males of
62.8F 15.4 years old and four females of 41.5F 17.7
years old). The mutations in the SPTLC1 gene of control
individuals were excluded by genotype analysis (Fig. 1).
Lymphocytes were infected with EBV virus to establish
cultures of transformed lymphocytes (lymphoblasts) as
described previously [20]. SPT activity was measured in
the microsomal fraction of protein extracts from trans-
formed lymphocytes as described in Methods and techni-
ques. Activity of the enzyme was linear with protein
concentration and had a steady state kinetics for 20 min(not shown). Specificity of SPT measurements was con-
firmed by the inhibitory effect of a SPT inhibitor, myriocin
(ISP1) [27] (Fig. 2B). Myriocin completely inhibited SPT
activity at concentrations over 10 nM (data not shown).
This is consistent with previous reports that myriocin
inhibited SPT activity at a nanomolar range [28]. The
average activity of SPT (Fig. 3B) was consistent with
previously published enzyme activities for these cells [19].
SPT activity in control cells varied to the greater extent
than in HSN1 cells (Fig. 3A), suggesting significant poly-
morphism of SPT activities in human population. SPT
activities in HSN1 cells were reduced by an average of
44% (P < 0.005) (Fig. 3B).
3.2. Synthesis of sphingolipids and sphingolipid content in
HSN1 cells
The rate of sphingolipid biosynthesis in HSN1 and
control cultures of transformed lymphocytes was measured
in intact cells by accumulation of sphingolipids after addi-
tion of radioactive serine for 2 h (Fig. 3). Similar data were
obtained after 24-h incubation with radioactive serine (data
not shown).
Fig. 3C,D shows no statistically significant difference
in the rate of total sphingolipid production between HSN1
and control cells. Labeling of individual sphingolipids—
sphingomyelin, glucosyl-ceramide, ceramide, sphinganine,
and spningosine—was also similar in HSN1 and control
cells (not shown). In general, there was no correlation
between SPT activity and sphingolipid biosynthesis rates
in 17 cultures of transformed lymphocytes used in this
study (Fig. 3E).
We also measured the steady state levels of six most
common sphingolipids in transformed lymphocytes from
HSN1 patients and unaffected individuals using liquid
Fig. 6. Viability of primary lymphocytes (A and B) and permeability of
their plasma membrane (C and D). Primary lymphocytes were isolated from
blood samples by Percoll centrifugation and stained with an apoptosis kit
(see Methods and techniques for details). (A) Average number of necrotic
white blood cells isolated from blood of control individuals (Control) and
HSN1 patients (HSN1). (B) Average expression of apoptosis marker,
phosphatidylserine, on plasma membrane of cells isolated from blood of
control individuals and HSN1 patients. (C) Primary lymphocytes were
incubated in the presence of PI. After addition of 0.01% Triton X-100, the
number of cell permeable to PI was calculated at regular time intervals up to
2 h. Fluorescence value 1000 a.u. (FL3 channel) was used as a cutoff value
for permeabilized cells. Percentage of permeable to PI cells was used to
calculate a steady state rate of Triton X-100 permeabilization, which reflects
the lipid composition of plasma membranes [31]. (D) Primary lymphocytes
isolated from blood of control individuals and HSN1 patients were
permeabilized at a steady state rate for 60 min.
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spectrometry [24,25]. The mass amounts of all sphingo-
lipids were statistically indistinguishable in HSN1 and
control cells (Fig. 4), which is consistent with the similar
rates of sphingolipid synthesis in HSN1 and normal cells
(Fig. 3).
3.3. Transformed lymphocyte proliferation and cell death
rates in HSN1 cells
It was shown previously that inhibition of SPT
activity by overexpression of mutant LCB1 in yeast or
CHO cell resulted in cell death [18,19]. However,
viability of transformed lymphocytes from HSN1 patients
were not assessed [19].
Here, we monitored cell proliferation and death in cul-
tures of HSN1 and control transformed lymphocytes. When
cells seeded at low concentration (0.25 106 cells/ml) in a
standard medium (10% FCS), they proliferated at steady
state rate for 72 h. We found no difference in the proliferation
rates between cultures of HSN1 and control cells (Fig. 5A).
There was also no difference in [3H]thymidine incorporation
rates in HSN1 and control cells (not shown).
In the previous studies, it was shown that extracellular
sphingolipids might compensate for the lower SPT activity,
whereas the replacement of serum with sphingolipid-free
medium supplement (Nutridoma) prevented growth of these
cells [29]. To determine if the availability of an exogenous
source of sphingolipids affects the viability of the trans-
formed lymphocytes from HSN1 patients, we replaced the
10% FCSwith 1%Nutridomamedium, which diminished the
viability of the cells, but affected HSN1 and control cells to
the same extent (Fig. 5A).
If cells were kept in culture longer than 3 days without
addition of fresh medium, they died by way of apoptosis
(Fig. 5B) and necrosis (Fig. 5C). There was no statistical
difference between HSN1 and control cells in death rates
either in 10% serum-supplemented or 1% Nutridoma-sup-
plemented (Fig. 5B,C).
3.4. Whole blood count, viability, and membrane perme-
ability of primary lymphocytes
In parallel with transformation, all samples of primary
lymphocytes from HSN1 patients were evaluated for the
possibility that the cells in vivo may display a different
pathology from those in culture. The whole blood counts
showed no statistical difference between HSN1 and control
blood samples, including lymphocyte counts (Table 1). We
also measured the percentage of dead lymphocytes and the
expression of the apoptosis marker phosphatidylserine [26].
Fig. 6A,B shows that neither the number of dead cells nor
phosphatidylserine expression, respectively, was different in
HSN1 and control cells.
It was shown previously that LCB1-deficient CHO
cells had altered sphingolipid contents in the plasmamembrane that changed their sensitivity to Triton X-
100 [30]. We have developed an assay to measure
permeability to PI in the presence of low concentrations
of Triton X-100 in primary lymphocytes. Incubation of
cells with 0.01% Triton X-100 increased the permeability
of the cells to PI with t1/2 = 40 min (Fig. 6C,D).
However, the sensitivity of HSN1 and control cells to
Triton X-100 was essentially the same (Fig. 6D), which
indicates that any subtle changes in lipid composition
(e.g., the cholesterol/sphingolipid ratio) [31]) in plasma
membrane of HSN1 cells has little effect on the stability
of the membranes as measured by this assay.
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It was shown previously that overexpression of HSN1-
like mutations in yeast or CHO cells results in inhibition of
SPT activity and sphingolipid synthesis, resulting in cell
death [18,19]. The authors hypothesize from these findings
that the neurodegeneration in HSN1 arises from this dom-
inant-negative effect of HSN1 mutations on SPT activity,
vis-a-vis, that mutant SPTLC1 replaces the normal SPTLC1
to form inactive complexes with SPTLC2. This mechanism
might account for the observation of a 75% reduction in
STP activity in transformed lymphocytes from HSN1
patients [19].
However, there are reasons to be cautious in extrapolat-
ing these findings to conclude that a dominant-negative
effect of HSN1 mutations is sufficient to explain the
pathophysiology of this disease. First, the numbers of
patients that have been analyzed for SPT activity is small,
and second, ectopic expression of a mutant LCB1 allele
probably produces much higher concentrations of the mu-
tant protein than occur HSN1 patients’ cells (thereby aber-
rantly replacing the wild-type protein and disrupting cell
function). In support of the latter reservation, human HSN1
and control cells appeared to express STPLC1 at the same
levels [19].
It must be generally acknowledged that data, obtained
using cell lines (i.e., CHO cells and EBV-transformed
lymphocytes), cannot directly extrapolated to the in vivo
events in neurons. Moreover, prior studies provided
conflicting accounts of changes in sphingolipid synthesis
due to SPTLC1 mutations, as both evidence of activation [1]
and inhibition [18,19] of sphingolipid synthesis were pre-
sented. While the reasons for the discrepancy are unclear,
other SPT-activity-related mechanisms of neurodegenera-
tion cannot be excluded. For example, accumulation of
mutant SPTLC1 was previously speculated as a possible
mechanism to introduce a novel toxic function into neurons
[19], but no evidence for such mechanism was provided to
date.
Because of prior discrepancy about the effects of
SPTLC1 mutation on sphingolipid synthesis, in this work,
we revisited the issues of possible mechanisms of HSN1 by
measuring SPT activity, cell proliferation, and death in
cultures of transformed lymphocytes from nine HSN1
patients, carrying the same SPTLC1 mutation. Our data
(even in combination with the four cell lines described
previously) showed that SPT activity in HSN1 cells is
essentially half of that of normal cells, consistent with the
fact that HSN1 patients carry two SPTLC1 alleles—one
normal and one mutant (Fig. 1). Providing that mutant allele
is inactive [18,19], the normal allele would account for
about 50% of wild-type activity unless the mutant is over-
expressed or able to inhibit multiple SPTLC2 proteins (in
which case the phenotype would be described as ‘‘dominant
negative’’). What we and others have observed is a reduc-
tion in activity consistent with the presence of about equalamounts of active and inactive enzyme, rather than a
dominant-negative phenotype.
In addition, there appeared to be relatively little (or no)
reduction in sphingolipid biosynthesis, sphingolipid content,
proliferation, or viability in the transformed lymphocytes
from the HSN1 patients. For the apparent discrepancy with
previously published data [19], we attribute to two factors:
the statistical size of samples and nature of mutations. We
evaluated nine patient cultures, all carrying predicted muta-
tion C133W in SPTLC1, whereas Bejaoui et al. [19]
assessed only one C133W and three C133Y cultures.
Therefore, it may be suggested that remaining 50% of
STP activity is sufficient to maintain the normal sphingo-
lipid homeostasis in these cells, presumably because the
cell may have more total SPT activity that it requires and
in vivo SPT is down-regulated. In contrast, higher over-
expression of a mutant STPCL1-like subunit in yeast or
CHO cells can result in cell death [18,19], as it often
occurs when some toxic proteins are overexpressed in cell
culture and in vivo [32].
The fact that a ca. 50% reduction in SPT activity appears
to have little impact on sphingolipid metabolism and cell
proliferation/viability may explain why HSN1 patients ap-
pear normal until the third decade of life. It is possible that
the expression of SPTCL1 and SPTCL2 are not as balanced
in aging neurons and a dominant-negative effect may
become manifested in these cells more profoundly than in
lymphocytes. It is also plausible that subtler changes in
sphingolipid metabolism are involved, such as the accumu-
lation of abnormal metabolites from dysregulation of these
pathways. It is also feasible that there could be accumulation
of mutant SPT in insoluble aggregates [19], as has been
suggested as a common pathogenic mechanism of other
common neurodegenerative disorders such Alzheimer’s or
Huttington’s diseases [33,34]. However, SPT1 aggregates
are yet to be discovered.Acknowledgements
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